What happened to btai’s IPO?
(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.
Where can I buy shares of btai?
Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Where can I buy bioxcel Therapeutics (btai)?
Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioXcel Therapeutics' stock price today?
How quickly does igalmi (btai) work?
• Igalmi demonstrated the onset of action as early as 20 minutes and a high response rate with both 120 mcg and 180 mcg doses in pivotal studies. • Price Action: BTAI shares are up 18.7% at $23.60 during the premarket session on the last check Wednesday.
Is BTAI a good stock to buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: BTAI) stock is to Strong Buy BTAI stock.
Should I buy BioXcel Therapeutics?
Bioxcel Therapeutics has 354.12% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
What does BioXcel therapeutics do?
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Will BTAI stock go up?
BioXcel Therapeutics Inc (NASDAQ:BTAI) The 9 analysts offering 12-month price forecasts for BioXcel Therapeutics Inc have a median target of 52.00, with a high estimate of 110.00 and a low estimate of 10.00. The median estimate represents a +329.40% increase from the last price of 12.11.
Where is BioXcel Therapeutics located?
Branford, ConnecticutBioXcel Therapeutics is located in Branford, Connecticut, United States .
What is BXCL701?
BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment. Approved and experimental immunotherapies often struggle to address cancers that appear “cold” or uninflamed.
Should I buy or sell BioXcel Therapeutics stock right now?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 sell...
What is BioXcel Therapeutics' stock price forecast for 2022?
6 equities research analysts have issued 12 month target prices for BioXcel Therapeutics' stock. Their forecasts range from $24.00 to $110.00. On a...
How has BioXcel Therapeutics' stock price performed in 2022?
BioXcel Therapeutics' stock was trading at $20.33 at the beginning of 2022. Since then, BTAI stock has decreased by 49.5% and is now trading at $10...
When is BioXcel Therapeutics' next earnings date?
BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for...
How were BioXcel Therapeutics' earnings last quarter?
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Monday, May, 9th. The company reported ($1.12) EPS for the qua...
Who are BioXcel Therapeutics' key executives?
BioXcel Therapeutics' management team includes the following people: Dr. Vimal D. Mehta Ph.D. , Founder, CEO, Pres, & Director (Age 61, Pay $1.4...
Who are some of BioXcel Therapeutics' key competitors?
Some companies that are related to BioXcel Therapeutics include Cassava Sciences (SAVA) , Myovant Sciences (MYOV) , MannKind (MNKD) , Zentalis...
What other stocks do shareholders of BioXcel Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA) ,...
When did BioXcel Therapeutics IPO?
(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share...
About BioXcel Therapeutics
Headlines
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development.
BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions
What Type Of Shareholders Own The Most Number of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares?
The positive news
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioXcel Therapeutics stock. View analyst ratings for BioXcel Therapeutics or view top-rated stocks.
The negative news
Since my previous coverage, a lot of positive news has come out of BTAI. The most important one is the NDA, which we just discussed. The other one is about its next pipeline program, acute agitation in dementia patients. The company just completed the phase 1b/2 TRANQUILITY trial in this indication. Key highlights of their announcement were:
Why is the stock down
Despite all this good news, the stock fell because BXCL501, despite meeting its primary endpoint, had a poor show in safety and tolerability in its phase 1b/2 opioid withdrawal study. Key highlights were:
Market
The confusing safety data from that one trial may have spooked investors; however, I believe the stock isn’t simply depressed, but rather it is correcting itself after an untenable bullish trend. The stock was trading at $6 in early December 2019. Then it announced the start of the pivotal phase 3 trials, and it began moving up.
Competition
In my previous coverage, I wrote that the company estimates that 13 million patients experience agitation every year in the U.S., with up to 22 million at risk, suffering from various neuropsychiatric disorders, including schizophrenia, bipolar disorder, dementia, delirium, and opioid withdrawal.
Financials
Antipsychotics and benzodiazepines are currently utilized to treat acute agitation. These have below-optimal safety and compliance issues. Antipsychotics have black box warnings for use in the elderly.
Bottom line
BTAI has a market cap of $777mn and a cash reserve of $194mn. Institutions are heavily invested in the company. Insiders, however, are not buying recently.
